HILLSIDE, N.J., March 7 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. , announces the introduction of its newly sized product line for sale in pharmacy departments of retail stores nationwide.
E. Gerald Kay, Chief Executive Officer of INB, said, "AgroLabs will be offering its Naturally Noni, Naturally Pomegranate and Naturally Thai Mangosteen liquid healthful nutritional products beginning March 13, 2006 in smaller bottles made especially for sale in non-club store distribution channels." "Expanding our product line to include smaller packaging for non-club stores will expand our customer base of mass marketers offering our products for sale and is an important element in our global distribution strategy for our propriety branded nutraceutical products. This is another step towards building the Company's name recognition as a leading provider of healthful nutritional products," Mr. Kay concluded.
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma Inc (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Integrated BioPharma IncCONTACT: Dina Masi, CFO of Integrated BioPharma Inc, +1-888-319-6962,d.masi@ibiopharma.com
